We scan new podcasts and send you the top 5 insights daily.
Clinical experience demonstrates that patients progressing on targeted agents can still respond to ADCs directed against the identical target if the mechanism or payload is switched. However, phase 3 clinical trial exclusions for prior topoisomerase-1 ADC exposure currently restrict the generation of sequencing data.
When sequencing antibody-drug conjugates, switching payloads reduces cross-resistance risk, and emerging evidence shows sequential activity even when targeting the same receptor with distinct payloads. However, clinicians express major concern that sequencing one topoisomerase-1 payload ADC after another could attenuate the second drug's activity, making the initial payload choice critical across gynecologic malignancies.
Dr. Liu highlights that sequentially administering ADCs remains active if clinicians change the cytotoxic payload, even when targeting the identical receptor. Conversely, emerging prospective breast cancer trials indicate that sequencing a topoisomerase I inhibitor ADC directly after another yields very low antitumor response rates.
When sequencing antibody-drug conjugates, clinical experience suggests that resistance to the chemotherapy payload is a primary driver of failure. Therefore, oncologists tend to avoid using another ADC with the same payload consecutively, preferring to switch both target and payload if possible.
Dr. O'Malley avoids using multiple ADCs with the same TOPA-1 payload sequentially due to a lack of data. However, he will reuse a target if the subsequent ADC has a different, non-cross-resistant payload, such as an anti-microtubulin. This is a practical strategy to manage resistance in a data-sparse environment, prioritizing payload diversity over simply switching targets.
Emerging data in urothelial cancer suggests a potential solution to the ADC sequencing problem. After treatment with a Nectin-4 targeted ADC, using a second Nectin-4 ADC with a different payload (topo-1 inhibitor instead of MMAE) still demonstrated efficacy.
The TROPION-PanTumor01 study showed that patients who progressed on the TROP2-ADC sacituzumab govitecan still achieved responses to a second TROP2-ADC, Dato-DXD. This suggests that targeting the same antigen with a different payload can overcome initial resistance, informing future treatment sequencing.
When sequencing antibody-drug conjugates (ADCs), the critical factor for efficacy may not be switching the antibody target, but rather switching the cytotoxic payload. For example, using an ADC with a different payload (like tizotumab vedotin’s MMAE) after one with a topoisomerase inhibitor (like TDXD) could overcome resistance, shifting the paradigm from 'ADC after ADC' to 'payload after payload'.
In the evolving landscape of antibody-drug conjugates (ADCs), the critical factor for sequencing is likely the cytotoxic payload, not just the target antigen. A patient could respond to an ADC with a different payload after progressing on another, even if both target the same protein.
As more antibody-drug conjugates (ADCs) become available, a key concern is resistance to the cytotoxic payload. If a tumor develops resistance to a topoisomerase-1 inhibitor from one ADC, it may not respond to other ADCs using the same payload, regardless of their different antibody targets, complicating future treatment sequencing.
Contrary to concerns about cross-resistance between HER2 antibody-drug conjugates (ADCs), retrospective data shows TDM-1 remains effective after progression on TDXD. This suggests the different cytotoxic payloads are key, allowing for effective sequencing and challenging the assumption that progression on one ADC class member precludes using another.